Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs

0
30

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here